| Literature DB >> 34148444 |
Qilin Yuan1, Hua-Yao Huang2, Xiao-Ling Chen3, Rong-Hua Chen1, Yixian Zhang2, Xiao-Bin Pan4, Jun-Nian Chen4, Nan Liu5,2, Houwei Du6.
Abstract
BACKGROUND AND AIMS: Physical inactivity is considered an important lifestyle factor for overweight and cardiovascular disease. We aimed to investigate the association between pre-existent physical inactivity and the risk of severe coronavirus disease 2019 (COVID-19).Entities:
Keywords: coronavirus disease 2019; physical inactivity; prognosis
Mesh:
Year: 2021 PMID: 34148444 PMCID: PMC8221695 DOI: 10.1177/17534666211025221
Source DB: PubMed Journal: Ther Adv Respir Dis ISSN: 1753-4658 Impact factor: 4.031
Demographic, clinical, laboratory, radiological characteristics, treatment, and outcome between patients with and without physical inactivity.
| Total ( | Inactivity ( | Activity ( |
| |
|---|---|---|---|---|
| Age, (years) mean ± SD | 61.8 ± 13.6 | 63.6 ± 13.8 | 58.7 ± 13.9 | 0.023 |
| Male, | 84 (51.2) | 54 (52.4) | 30 (49.2) | 0.688 |
| Current smoker, | 17 (10.4) | 9 (8.7) | 8 (13.1) | 0.374 |
| Regular drinker, | 3 (1.8) | 2 (1.9) | 1 (1.6) | >0.999 |
| Hypertension, | 52 (31.7) | 37 (35.9) | 15 (24.6) | 0.132 |
| Diabetes, | 31 (18.9) | 19 (18.4) | 12 (19.7) | 0.846 |
| Dyslipidemia, | 63 (38.4) | 39 (37.9) | 24 (39.3) | 0.851 |
| Atrial fibrillation, | 10 (6.1) | 8 (7.8) | 2 (3.3) | 0.410 |
| Overweight, | 55 (33.5) | 37 (35.9) | 18 (29.5) | 0.400 |
| Previous stroke, | 6 (3.7) | 6 (5.8) | 0 (0.0) | 0.085 |
| Chronic obstructive pulmonary disease, | 12 (7.3) | 10 (9.7) | 2 (3.3) | 0.223 |
| Coronary heart disease, | 18 (11.0) | 14 (13.6) | 4 (6.6) | 0.257 |
| Renal impairment, | 25 (15.2) | 21 (20.4) | 4 (6.6) | 0.031 |
| Digestive disease, | 15 (9.1) | 8 (7.8) | 7 (11.5) | 0.426 |
| Immunosuppressives, | 3 (1.8) | 1 (1.0) | 2 (3.3) | 0.643 |
| Tumor, | 13 (7.9) | 11 (10.7) | 2 (3.3) | 0.163 |
| Wet market exposure, | 2 (1.2) | 2 (1.9) | 0 (0.0) | 0.530 |
| Clinical symptoms | ||||
| Fever, | 115 (70.1) | 70 (68.0) | 45 (73.8) | 0.432 |
| Dry cough, | 104 (63.4) | 65 (63.1) | 39 (63.9) | 0.915 |
| Productive cough, | 23 (14.0) | 13 (12.6) | 10 (16.4) | 0.501 |
| Fatigue, | 57 (34.8) | 34 (33.0) | 23 (37.7) | 0.542 |
| Muscle or joint ache, | 21 (12.8) | 15 (14.6) | 6 (9.8) | 0.381 |
| Thoracalgia, | 31 (18.9) | 21 (20.4) | 10 (16.4) | 0.528 |
| Sore throat, | 23 (14.0) | 14 (13.6) | 19 (14.8) | 0.836 |
| Diarrhea, | 13 (7.9) | 11 (10.7) | 2 (3.3) | 0.163 |
| Catarrh, | 6 (3.7) | 2 (1.9) | 4 (6.6) | 0.275 |
| Anorexia, | 48 (29.3) | 27 (26.2) | 21 (34.4) | 0.264 |
| Shortness of breath, | 65 (39.6) | 40 (38.8) | 25 (41.0) | 0.786 |
| Headache, | 19 (11.6) | 11 (10.7) | 8 (13.1) | 0.638 |
| Total symptoms (IQR) | 3 (2–4) | 3 (2–4) | 3 (2–4) | 0.935 |
| Routine blood examinations | ||||
| Decreased leucocytes, | 11 (6.7) | 6 (5.8) | 5 (8.2) | 0.792 |
| Decreased lymphocytes, | 55 (33.5) | 37 (35.9) | 18 (29.5) | 0.400 |
| Decreased hemoglobin, | 42 (25.6) | 25 (24.3) | 17 (27.9) | 0.610 |
| Decreased platelets, | 14 (8.5) | 11 (10.7) | 3 (4.9) | 0.324 |
| Increased ALT or AST, | 58 (35.4) | 35 (34.0) | 23 (37.7) | 0.630 |
| Increased LDH, | 50 (30.7) | 32 (31.4) | 18 (29.5) | 0.803 |
| Complications | ||||
| Acute stroke, | 3 (1.8) | 3 (2.9) | 0 (0.0) | 0.295 |
| Shock, | 3 (1.8) | 3 (2.9) | 0 (0.0) | 0.295 |
| CT findings, | 0.338 | |||
| Unilateral pneumonia, | 26 (15.9) | 13 (12.6) | 13 (21.3) | |
| Bilateral pneumonia, | 86 (52.4) | 56 (54.4) | 30 (49.2) | |
| Multiple mottling and ground-glass opacity, | 52 (31.7) | 34 (33.0) | 18 (29.5) | |
| Treatment | ||||
| Oxygen therapy, | 0.214 | |||
| Nasal cannula, | 79 (48.2) | 48 (46.6) | 31 (50.8) | |
| Medical mask, | 5 (3.0) | 4 (3.9) | 1 (1.6) | |
| High solution, | 5 (3.0) | 5 (4.9) | 0 (0.0) | |
| Invasive ventilation, | 3 (1.8) | 3 (2.9) | 0 (0.0) | |
| Glucocorticoid, | 20 (12.2) | 13 (12.6) | 7 (11.5) | 0.828 |
| Antibacterial, | 117 (71.8) | 76 (74.5) | 41 (67.2) | 0.317 |
| Antivirus, | 158 (96.3) | 99 (96.1) | 59 (96.7) | >0.999 |
| Chinese traditional medicine, | 156 (95.1) | 99 (96.1) | 157 (93.4) | 0.694 |
| Outcomes | ||||
| Cured at discharge, | 103 (62.8) | 67 (65.0) | 36 (59.0) | 0.440 |
| Death, | 6 (3.7) | 6 (5.8) | 0 (0.0) | 0.085 |
| Severe COVID-19 | 29 (17.4) | 26 (25.2) | 3 (4.9) | 0.002 |
Decreased means below the lower limit of the normal range: leucocytes (×109/L; normal range 3.5–9.5); lymphocytes (×109/L; normal range 1.1–3.2); platelets (×109/L; normal range 125.0–350.0); hemoglobin (g/L; normal range 130.0–175.0). ALT: U/L; normal range 0–40; AST: U/L; normal range 0–40; LDH: U/L; normal range 109–245, data available in 163 patients.
ALT, alanine transaminase; AST, alanine aminotransferase; COVID-19, coronavirus disease 2019; CT, computed tomography; IQR, interquartile range; LDH, lactate dehydrogenase; SD, standard deviation.
Association between physical inactivity and severe COVID-19.
| OR | 95% CI | ||
|---|---|---|---|
| Unadjusted | 6.53 | 1.88–22.62 | 0.003 |
| Age and sex adjusted | 4.98 | 1.38–17.964 | 0.014 |
| Age, sex, and hypertension adjusted | 4.99 | 1.38–18.06 | 0.014 |
| Age, sex, and diabetes adjusted | 5.05 | 1.39–18.27 | 0.014 |
| Age, sex, and CHD adjusted | 5.03 | 1.39–18.19 | 0.014 |
| Age, sex, and tumor adjusted | 4.82 | 1.32–17.54 | 0.017 |
| Age, sex, and renal impairment adjusted | 4.40 | 1.21–16.03 | 0.025 |
| Age, sex, and current smoker adjusted | 4.89 | 1.35–17.65 | 0.015 |
| Age, sex, and overweight adjusted | 4.77 | 1.31–17.30 | 0.018 |
| Age, sex, and stroke adjusted | 4.47 | 1.23–16.24 | 0.023 |
| Multivariable | 4.12 | 1.12–15.14 | 0.033 |
Multivariable = adjustment for age, sex, stroke, and overweight.
CHD, coronary heart disease; CI, confidence interval; COVID-19, coronavirus disease 2019; OR, odds ratio.